Corporate Banner
Satellite Banner
Immunology
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

£14 Million Boost to Life Science Cluster at Milton Park, Oxford

Published: Wednesday, January 29, 2014
Last Updated: Wednesday, January 29, 2014
Bookmark and Share
A share of a £100 million Government cash injection is awarded to accelerate growth and jobs in Enterprise Zones across the UK.

Milton Park will receive a grant of up to £7 million to support the development of a £14 million, 40,000 sq ft specialist science centre for small and growing businesses within the life sciences sector. The balance of funding will be provided by park owners, MEPC. The new facility will be called the Milton Science Centre (MSc).

As part of today's announcement, Ed Vaizey Government Minister and Local MP visited Milton Park to deliver the good news and meet representatives from some of the 50 strong life sciences businesses already based at Milton Park.

Ed Vaizey was also shown around the laboratories of Immunocore, a privately owned, clinical-stage biotechnology company developing novel biological drugs to treat cancer and viral disease and a great example of a successful Oxfordshire Life Science Business. Ed Vaizey added: “Today’s announcement underlines this government's strong commitment to the UK life sciences sector. It will also lead to a significant step in the development of the Oxfordshire cluster. Milton Park is one of the top performing enterprise zones across the country and, with its new Local Development Order simplifying planning and track record of success,  I have every confidence that this project will be delivered quickly and help produce many more great life sciences businesses like Immunocore.”

James Dipple, Managing Director of Milton Park, explains, " This announcement is great news for Oxfordshire, as it will further strengthen the county's highly successful life sciences cluster.  The Government's contribution will help us build on the great environment we already have here and provide these small and growing life sciences businesses with the specialist accommodation they really need.  This is the culmination of a county wide team effort across the public and private sectors and I am grateful to all those who helped to support the bid.  A special thanks must go to the District and County Councils, the Local  Enterprise Partnership and OBN. I must also say a big thank you to our local MP Ed Vaizey. Public-private partnerships such as this, with business investing alongside Government, create opportunities for local employment, national success and healthcare advances which will be used around the world."

During the last six months, Immunocore has entered into major partnerships with leading pharmaceutical companies, Genentech, GlaxoSmithKline and MedImmune, part of AstraZeneca, and has doubled in size to nearly 100 staff.

Eva-Lotta Allan, Chief Business Officer at Immunocore, commented: "We welcome  the Government's decision to work in partnership with Milton Park to enhance the life science infrastructure within the Science Vale Enterprise Zone. Adding a dedicated hub for innovation to the existing facilities here, will help to ensure we continue to attract the best scientists as we progress the development of new treatments that could help many thousands of cancer patients."

Immunocore is one of the ten fastest growing life science companies based on Milton Park, featured in a publication launched by OBN earlier this month. The book, titled ‘An Evolution: The Story of Milton Park Life Sciences Cluster’, celebrates the life sciences cluster at Milton Park and includes interviews from senior personnel from each company.

Jon Rees, CEO of OBN, adds, “We were delighted to support this bid. The new facility will address a limiting step in Oxfordshire life sciences cluster and is exactly what it needs. The provision of wet labs for start-ups is the obvious next stage of evolution for the Milton Park life science cluster. ”



Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More than 4,800+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Flu Vaccine May Reduce Death Risk of Type 2 Diabetes
New research suggests that a new flu vaccine may reduce probability of type 2 diabetes patients being hospitalised with stroke and heart failure.
Gut Bacteria Older than Human Species
Some bacteria have lived in the human gut since before we were human, suggesting evolution could have a larger role inhuman bacterial makeup.
Evidence of Mosquito Transmitting Zika
A direct link between the Yellow fever mosquito and Zika transmission has been found following investigation into selective mosquito control.
Antibody-Based Drug for Multiple Sclerosis
New antibody-based drug paves the way for new strategies for controlling and treating multiple sclerosis.
Three-Drug Combinations Counter Antibiotic Resistance
Research shows that combinations of three different antibiotics can treat resistant bacteria, even if they are ineffective independently.
Mapping Zika’s Routes to Developing Fetus
UC researchers show how Zika virus travels from a pregnant woman to her fetus, and also identified a drug that could stop it.
Treating HIV with Cancer-Fighting Gene Shows Promise
A type of gene immunotherapy that has shown promising results against cancer could also be used against HIV.
Protein Teams Activate T-Cells
Caltech researchers have discovered T-cell genetic switching is controlled by four proteins acting in a multi-tiered fashion.
'Antigen-Presenting Cell' Defends Against Cancer
Through advanced imaging, researchers have identified cells that encourages increases in immune system cancer defences.
Zika Epidemic Likely to End Within Three Years
A team of scientists has predicted that the current Zika epidemic is likely to end within three years because there will be too few people left to infect.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,800+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!